PBM
DCTH icon

Propel Bio Management’s Delcath Systems DCTH Stock Holding History

Propel Bio Management’s Portfolio DCTH Stock Details DCTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Sell
871,460
-108,238
-11% -$1.2M 5.74% 5
2026
Q1 		$9.16M Buy
979,698
+541,189
+123% +$5.24M 5.77% 4
2025
Q4 		$4.43M Hold
438,509
– – 3.78% 9
2025
Q3 		$4.71M Buy
438,509
+212,457
+94% +$2.37M 4.72% 8
2025
Q2 		$3.07M Buy
226,052
+48,452
+27% +$676K 3.73% 8
2025
Q1 		$2.26M Buy
177,600
+160,600
+945% +$2.28M 2.63% 10
2024
Q4 		$205K Buy
+17,000
New +$179K 0.2% 18

Other funds holding DCTH

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Algert Global San Francisco, California $8.43B AUM 80.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $4.41B AUM 90.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Propel Bio Management's DCTH Position: Q2 2026 in Review

Propel Bio Management reduced its Delcath Systems (DCTH) stake by 11% in Q2 2026, selling an estimated $1.2M and leaving 871,460 shares worth $11M. The position accounts for 5.74% of the portfolio, ranked #5.

Propel Bio Management first reported a position in DCTH in Q4 2024 and has held it in 7 quarters since. 120 funds tracked by Wall St. Rank hold DCTH as of Q2 2026.

  • Propel Bio Management held 871,460 shares of Delcath Systems worth $11M as of Q2 2026.
  • Propel Bio Management sold 108,238 Delcath Systems shares in Q2 2026, an estimated $1.2M.
  • Delcath Systems made up 5.74% of Propel Bio Management's portfolio in Q2 2026, its #5 holding.
  • Propel Bio Management first reported a position in Delcath Systems in Q4 2024 and has held it in 7 quarters since.
  • 120 funds tracked by Wall St. Rank held Delcath Systems as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.